author-photo

Karl Ziegelbauer

Bayer
Bayer HealthCare Pharmaceuticals

120

Papers

2880

Citations

Citation Trend

Filter By

Papers (120) Sort By

Journal Conference Others

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase

2020 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (9)
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (36)
Abstract LB-075: Increased T cell- activation resulting from the combination of the anti-CEACAM6 function-blocking antibody BAY 1834942 with checkpoint inhibitors targeting either PD-1/PD-L1 or TIM-3

2019 Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

2019 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (30)
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (22)
The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models.

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (53)
Abstract 3926: MSLN-TTC (BAY 2287411) induces immunogenic cell death and secretion of pro-inflammatory cytokinesin vitroand triggers an immune memory effect against a mouse tumor model

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma

2019 International Journal of Oncology
Show All
- Source
- Cite
- Save
Citations (13)
Abstract 3937: MSLN-TTC (BAY 2287411) demonstrates increased activity in comparison to standard of care chemotherapy in models of acquired drug resistance

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Synergistic Effect of a Mesothelin Targeted Thorium-227 Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

2019 The Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (25)